PCOS Has an Official New Name: What the Lancet's May 2026 Announcement Means for Your Fertility

On May 12, 2026, something happened that women with PCOS have been waiting for without knowing to wait for it.

A landmark paper published in The Lancet announced the official rename of Polycystic Ovary Syndrome to PMOS: Polyendocrine Metabolic Ovarian Syndrome. The result of 14 years of global collaboration, more than 22,000 survey responses, and input from 56 patient and professional organizations across the world.

This is not a rebranding. It is a clinical acknowledgment that the old name pointed care in the wrong direction for nearly 90 years — and that the consequences of that have been real and carried primarily by the women trying to get answers.

If you have been diagnosed with PCOS and have spent years feeling like the explanation never quite explained anything — this is why.

What the Lancet paper actually found

The core finding that drove the rename: there is no actual increase in abnormal ovarian cysts in this condition. The defining feature the condition was named after — the cysts — is not a consistent or reliable marker of the underlying syndrome.

Many women with classic PCOS have no cysts on ultrasound at all. Many women with visible follicles on ultrasound don't have the syndrome. The structure the condition was named after was always a consequence, not a cause — and naming it that way meant generations of clinicians and patients were anchored to the wrong thing.

The paper also confirmed that PMOS affects multiple body systems — not just the reproductive organs — and that its cardiometabolic consequences are as clinically significant as its reproductive ones. Women with PMOS carry elevated risk for insulin resistance, prediabetes, type 2 diabetes, and cardiovascular disease — risks that standard PCOS management has historically underemphasized.

A 3-year global transition period is now underway, with full implementation expected in the 2028 International Guideline update. For the next few years, you'll see both names in clinical settings. They refer to the same condition.

Why the old name was always the wrong name

Polycystic Ovary Syndrome was named in 1935 by Stein and Leventhal, who described women with enlarged ovaries, irregular periods, and signs of androgen excess. They named what they could see.

The problem: what they saw was a consequence, not a cause. Those stalled follicles form because the hormonal environment inside the ovary disrupts normal follicle maturation. That disruption is driven by dysregulated insulin signaling and elevated androgens. Nothing structurally wrong with the ovary creates it — the ovary is responding to a systemic signal.

By naming the condition after its most visible feature, clinical attention anchored to the ovaries and the cysts while the metabolic system producing the signal those ovaries were responding to went largely unaddressed. That's the gap. That's where women fell through.

What PMOS actually means: breaking down the new name

Each word in the new name carries clinical weight.

Polyendocrine reflects that this is not a single-hormone condition. It involves the interaction of insulin, androgens (testosterone, androstenedione), cortisol, and in many cases thyroid function. The disruption is systemic, not localized to one gland or one pathway.

Metabolic reflects what drives the condition at its root. Insulin resistance is present in approximately 70 to 95 percent of women with PMOS, regardless of body weight. When cells resist insulin's signaling, the body compensates by producing more insulin — and elevated circulating insulin then signals the ovaries to produce more androgens. Elevated androgens disrupt follicle maturation and ovulation. This is the mechanism. It starts in metabolism, not in the ovary.

Ovarian acknowledges that the ovaries are affected — just not the cause. They're where the disruption becomes visible: in irregular cycles, in stalled follicles, in the androgens produced when the metabolic system is dysregulated.

What this means if you're trying to conceive

The rename matters for fertility care because it shifts the question. When the condition is understood as metabolic and polyendocrine — not just an ovarian structural issue — the logical focus becomes insulin regulation, androgen pathways, inflammation, and the hormonal cascades that determine whether ovulation happens and whether the follicular environment supports a viable egg.

That's root-cause thinking. And it's exactly why so many women with PCOS have felt dismissed by care that managed their cycles without ever investigating what was driving the irregularity in the first place.

A diagnosis is a starting point, not a sentence. If you've been told you have PCOS and you're trying to conceive, the question worth asking is not just "how do we induce ovulation" — it's what is driving the hormonal disruption in your specific body, and what does it need to regulate.

That's the investigation I do with clients inside The Egg Awakening Method. If you have PCOS — or suspect you might — and you want to understand what's actually happening beneath the diagnosis, I'd love to have a conversation.